Table 3.

Adverse events according to sequential order of treatment

	First-line			Second-line
	Group A IP	Group B EP	P-value	Group B IP	Group A EP	P-value
Anemia	2	5	0.249	6	9	0.195
Neutropenia	11	23	0.015	22	26	0.486
Thrombocytopenia	9	7	0.316	12	9	0.238
Diarrhea	10	2	0.012	11	4	0.017

Note: Patients received IP until progression and then EP (group A), or the reverse treatment sequence (group B).

Abbreviations: IP, irinotecan/cisplatin; EP, etoposide/cisplatin.